Members Only

BLOGBU$TER has dropped beneath the radar, accepting referenced members only. We combine the cutting edge of drug development expertise with the utmost focus. We leverage shared knowledge of the highest quality biotech professionals.

Recent Posts:

October 17, 2017:  J&J Q3 Report

October 16, 2017:  The Next Move … (4)

October 10, 2017:  Tisotumab Progress

October 07, 2017:  The Crap Scale

October 07, 2017:  Pathetic Fallacy (update)

October 05, 2017:  Autumn

October 01, 2017:  Last End Game (Part 3)

September 29, 2017:  Last End Game (Part 2)

September 27, 2017:  Last End Game (Part 1)

September 27, 2017:  The Growing Gap

September 19, 2017:  FDA stops Roche

September 15, 2017:  Bavarian comes to a stop

September 07, 2017:  Et voilà Astra/Celgene

September 07, 2017:  BMS hits the same wall

September 01, 2017:  Janssen ends MG’s program

September 01, 2017:  Merck hits another wall

August 29, 2017:  Seattle opts-in

August 24, 2017:  Alcyone: Bull’s Eye !

August 23, 2017:  Myelodysplastic Syndromes

August 22, 2017:  Another Superstar

August 11, 2017:  The RC Continues …

August 09, 2017:  Genmab Reports Q2

August 05, 2017:  Valuation Intricacies

August 03, 2017:  Teva implodes …

July 27, 2017:  Astra hits a Wall …

July 24, 2017:  Careful with CAR-T

July 18, 2017:  J&J Q2 Report

July 09, 2017:  In the Doldrums …

July 01, 2017:  Fall Down 7 Times …

June 23, 2017:  Upside Down …

June 22, 2017:  Seattle hits a Road Block

June 16, 2017:  Dara-Pom-Dex approved

June 14, 2017:  Great Interview …

June 13, 2017:  Chaos & Controversy

June 13, 2017:  Merck hits a wall …

June 11, 2017:  The Ultimate Payoff …

June 6, 2017:  ASCO 2017 Data

June 1, 2017:  Citi to 1,800

May 19, 2017:  ‘Mega’ Status …

May 12, 2017:  General Prayers Day

May 11, 2017:  Roche Hits A Wall !

May 8, 2017:  DenmarkBridge Award

April 29, 2017:  Salut Sanofi …

April 28, 2017:  EMA Approval

April 21, 2017:  Chicago June 2–6

April 19, 2017:  Global Biologics Production

April 18, 2017:  J&J Q1 Report

April 17, 2017:  Canadian Approval

April 14, 2017:  Egg On Their Face

April 12, 2017:  Easter Weekend

April 7, 2017:  The Second DuoBody 

April 4, 2017:  No Funch !

April 1, 2017:  April Fools Day

March 30, 2017:  Better Opportunities … 

March 26, 2017:  A Top-Five Player

March 16, 2017:  NICE playing hard ball …

March 15, 2017:  A Wake Up Call

March 14, 2017:  Racing to Catch up

March 5, 2017:  The Ultimate Leap Forward

February 24, 2017:  A Positive Opinion

February 22, 2017:  2016 Full Year Results

February 19, 2017:  The Winner is …

February 15, 2017:  Pathetic Fallacy (2)

February 9, 2017:  Losing $80 billion …!

February 8, 2017:  Even More Applications …?

February 6, 2017:  Another new high …

February 01, 2017:  Leap Frog Antibodies

January 26, 2017:  J&J’s paying $30 billion

January 21, 2017:  The Key to Success (2)

January 17, 2017:  The Key to Success

January 17, 2017:  Jefferies, JPM, Goldman & Nordea Raising

January 08, 2017:  A New Closing-High

January 06, 2017:  Eat Humble Pie

January 04, 2017:  The JPM Conference next

December 30, 2016:  Let’s get going…

December 27, 2016:  Oeps…

December 27, 2016:  The Bigger Plan

December 21, 2016:  Where’s the charm…?

December 20, 2016:  Overtaking left & right…

December 17, 2016:  Disruptive Innovation

December 17, 2016:  Merci, chérie…

December 14, 2016:  Third time’s the charm (2)

December 12, 2016:  Arzerra Label Expansion (2)

December 6, 2016:  ASH 2016 (2)

December 5, 2016:  ASH 2016 (1)

November 30, 2016:  Third time’s the charm

November 28, 2016:  J&J after part of Actelion…

November 27, 2016:  FDA approval 2nd-line

November 23, 2016:  Continuing problems…

November 20, 2016:  Moving Closer…

November 10, 2016:  AXL into the clinic

November 10, 2016:  CMD. Beyond Darzalex…

November 9, 2016:  A clean GOP sweep

November 8, 2016:  The Fourth DuoBody…

November 4, 2016:  The cows come home…

November 3, 2016:  A Wave of Raises…

November 2, 2016:  An Excellent 3rd Quarter

November 1, 2016:  Ninlaro, blah, blah…

October 29, 2016:  ASH 2016 approaching…

October 26, 2016:  A Dem Sweep…?

October 24, 2016:  Nordea in the lead (2)

October 18, 2016:  Goldman ups the ante…

October 16, 2016:  Deutsche: shocking…

October 8, 2016:  The Apple of Biotech…

October 6, 2016:  NEJM Publishing Pollux

October 5, 2016:  Solid Tumors (2)

October 3, 2016:  Darzalex Accelerating

September 30, 2016:  Citigroup (2)

September 27, 2016:  Another One Bites the Dust…

September 22, 2016:  Institutional Shareholders Update (2)

September 19, 2016:  Natural Killer (NK) Cells

September 10, 2016:  A Giant Sinkhole…

August 31, 2016:  A Unit Blow Up…

August 31, 2016:  Arzerra Label Expansion

August 28, 2016:  A Fortunate Turn

August 27, 2016:  Of the highest importance

August 23, 2016:  What a Difference…

August 20, 2016:  Solid Tumors

August 14, 2016:  Me-tooism

August 14, 2016:  2Q2016 Report

August 10, 2016:  Getting Real After All…

July 30, 2016:  Ten Years After

July 27, 2016:  Breakthru…

July 23, 2016:  Institutional Shareholders Update

July 17, 2016:  The Next Move … (3)

July 08, 2016:  Another Blow-up…

July 07, 2016:  A Veritable Cesspool

July 06, 2016:  BMS eats Cormorant

July 04, 2016:  Drowsy as a Dormouse…

June 30, 2016:  Something’s Brewing…

June 28, 2016:  The Esemplastic Gift

June 24, 2016:  The Flash Correction…

June 16, 2016:  TC-Week …

June 14, 2016: TC-Day … (4)

June 11, 2016: TC-Day … (3)

June 11, 2016: TC-Day … (2)

June 09, 2016: TC-Day …

June 06, 2016:  Back in Frogland

June 03, 2016:  Dawdlers

June 01, 2016:  Pricing

May 30, 2016:  Crocevia

May 26, 2016:  News from Syracuse

May 24, 2016:  Rapid Fire

May 23, 2016:  EMA Approval

May 23, 2016:  Danske

May 21, 2016:  A Break

May 18, 2016:  Pollux Data

May 18, 2016:  Splitting up

May 14, 2016:  A Billion Dollars

May 11, 2016:  1st Quarter Reports

May 10, 2016:  Barriers

May 06, 2016:  Gilead

May 06, 2016:  100,000 hits

May 05, 2016:  Trial News

May 01, 2016:  The Paragon

April 27, 2016:  Action

April 24, 2016:  One + One

April 19, 2016:  New Insights

April 16, 2016:  Leading or Lagging Indicator